BioCentury
ARTICLE | Company News

Avexa, Shire Pharmaceuticals Group plc deal

January 24, 2005 8:00 AM UTC

SHP granted AVX a license to SPD754, a cytidine analog nucleoside reverse transcriptase inhibitor (NRTI) to treat HIV. SPD754 has completed Phase IIa trials. Avexa is responsible for global developmen...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article